Asset
NC-410
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04408599 | phase1_2 | terminated | 2020-06-10 | 2023-07-06 | NextCure, Inc. | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors |
| NCT05572684 | phase1_2 | terminated | 2022-10-06 | 2025-04-30 | NextCure, Inc. | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.